PL2011486T3 - Farmaceutyczne kompozycje rifaksyminy - Google Patents
Farmaceutyczne kompozycje rifaksyminyInfo
- Publication number
- PL2011486T3 PL2011486T3 PL08252198T PL08252198T PL2011486T3 PL 2011486 T3 PL2011486 T3 PL 2011486T3 PL 08252198 T PL08252198 T PL 08252198T PL 08252198 T PL08252198 T PL 08252198T PL 2011486 T3 PL2011486 T3 PL 2011486T3
- Authority
- PL
- Poland
- Prior art keywords
- rifaximin
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN968KO2007 | 2007-07-06 | ||
EP08252158 | 2008-06-23 | ||
EP08252198.0A EP2011486B2 (en) | 2007-07-06 | 2008-06-26 | Pharmaceutical compositions of rifaximin |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2011486T3 true PL2011486T3 (pl) | 2013-01-31 |
PL2011486T5 PL2011486T5 (pl) | 2016-09-30 |
Family
ID=40091777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08252198.0T PL2011486T5 (pl) | 2007-07-06 | 2008-06-26 | Farmaceutyczne kompozycje rifaksyminy |
Country Status (8)
Country | Link |
---|---|
EP (4) | EP3714878B1 (pl) |
CY (1) | CY1113068T1 (pl) |
DK (1) | DK2011486T3 (pl) |
ES (3) | ES2905795T3 (pl) |
HR (1) | HRP20120665T1 (pl) |
PL (1) | PL2011486T5 (pl) |
PT (1) | PT2011486E (pl) |
SI (1) | SI2011486T1 (pl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
EP3620153A1 (en) * | 2007-07-06 | 2020-03-11 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
EP4342465A3 (en) | 2008-10-02 | 2024-06-12 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
WO2010148040A1 (en) * | 2009-06-15 | 2010-12-23 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
AU2010313078A1 (en) * | 2009-10-27 | 2012-05-24 | Lupin Limited | Solid dispersion of rifaximin |
US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
PT2593463T (pt) * | 2010-07-12 | 2020-09-17 | Salix Pharmaceuticals Ltd | Formulações de rifaximina e usos das mesmas |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
EP2890366A1 (en) | 2012-08-28 | 2015-07-08 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at least one of them is in the form of mini-tablets |
EP2927235B1 (en) * | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
JP6576953B2 (ja) | 2014-05-12 | 2019-09-18 | アルファシグマ ソシエタ ペル アチオニ | リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用 |
CA3038312A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
AU2018211305B2 (en) | 2017-04-26 | 2019-07-25 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
US11129862B2 (en) * | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
CN108658673A (zh) * | 2018-06-27 | 2018-10-16 | 安徽瑞然生物药肥科技有限公司 | 一种用于缓释肥料的包膜材料及其制备方法 |
CN109021187B (zh) * | 2018-08-24 | 2019-09-06 | 中山大学 | 玉米醇溶蛋白-聚磺基甜菜碱两亲性缀合物及其制备方法与应用 |
CN109663150B (zh) * | 2018-12-29 | 2022-01-14 | 广州贝奥吉因生物科技股份有限公司 | 一种心肌修复水凝胶材料及其制备方法 |
WO2020208140A1 (en) | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
BR112022003500A2 (pt) * | 2019-09-24 | 2022-05-24 | Bausch Health Ireland Ltd | Formulações líquidas de rifaximina |
CN111317824B (zh) * | 2020-02-29 | 2022-04-12 | 复旦大学 | 一种载多肽药物的口服纳米制剂及其制备方法 |
CA3184054A1 (en) * | 2020-06-26 | 2021-12-30 | Jacob Cole | Targeted release rifaximin compositions |
US20240415809A1 (en) * | 2021-10-19 | 2024-12-19 | Zydus Lifesciences Limited | Pharmaceutical combinations |
GR1010652B (el) * | 2023-04-20 | 2024-03-12 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιμικροβιακο παραγοντα και μεθοδος για την παρασκευη αυτου |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1253711B (it) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) † | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
ITMI20041295A1 (it) † | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
US20060045865A1 (en) † | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
-
2008
- 2008-06-26 ES ES20160395T patent/ES2905795T3/es active Active
- 2008-06-26 PL PL08252198.0T patent/PL2011486T5/pl unknown
- 2008-06-26 EP EP20160395.8A patent/EP3714878B1/en active Active
- 2008-06-26 ES ES11176043T patent/ES2798253T3/es active Active
- 2008-06-26 ES ES08252198.0T patent/ES2389358T5/es active Active
- 2008-06-26 EP EP08252198.0A patent/EP2011486B2/en active Active
- 2008-06-26 PT PT08252198T patent/PT2011486E/pt unknown
- 2008-06-26 SI SI200830741T patent/SI2011486T1/sl unknown
- 2008-06-26 DK DK08252198.0T patent/DK2011486T3/da active
- 2008-06-26 EP EP11176043.5A patent/EP2420226B1/en active Active
- 2008-06-26 EP EP14186563.4A patent/EP2837378A1/en not_active Withdrawn
-
2012
- 2012-08-17 HR HRP20120665AT patent/HRP20120665T1/hr unknown
- 2012-08-23 CY CY20121100760T patent/CY1113068T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2011486B2 (en) | 2015-08-12 |
EP2420226B1 (en) | 2020-03-04 |
EP2011486A1 (en) | 2009-01-07 |
EP3714878B1 (en) | 2022-01-19 |
PT2011486E (pt) | 2012-08-24 |
EP3714878A1 (en) | 2020-09-30 |
HRP20120665T1 (hr) | 2012-10-31 |
PL2011486T5 (pl) | 2016-09-30 |
EP2837378A1 (en) | 2015-02-18 |
ES2389358T3 (es) | 2012-10-25 |
EP2420226A1 (en) | 2012-02-22 |
ES2905795T3 (es) | 2022-04-12 |
CY1113068T1 (el) | 2016-04-13 |
ES2798253T3 (es) | 2020-12-10 |
SI2011486T1 (sl) | 2012-10-30 |
DK2011486T3 (da) | 2012-09-03 |
EP2011486B1 (en) | 2012-05-23 |
ES2389358T5 (es) | 2016-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201000437B (en) | Pharmaceutical compositions of rifaximin | |
PL2011486T3 (pl) | Farmaceutyczne kompozycje rifaksyminy | |
IL247741A0 (en) | pharmaceutical preparations | |
ZA200900347B (en) | Preparation of pharmaceutical compositions | |
EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
EP2222313A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
ZA200905134B (en) | Compositions of stable tiacumicins | |
RS58950B1 (sr) | Farmaceutske kompozicije koje sadrže korteksolon-17-alfa-propionat | |
GB0608724D0 (en) | Novel Pharmaceutical Compositions | |
GB0610322D0 (en) | Novel pharmaceutical compositions | |
EP2146695A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0709811D0 (en) | Pharmaceutical compositions | |
SI2002825T1 (sl) | Farmacevtski sestavki, ki obsegajo orlistat | |
GB0707127D0 (en) | Pharmaceutical compositions | |
GB0716907D0 (en) | Pharmaceutical powder compositions | |
GB0712454D0 (en) | Pharmaceutical compositions | |
GB2454923B (en) | Pharmaceutical compositions | |
IL201394A0 (en) | Niacin - based pharmaceutical compositions | |
HU0700755D0 (en) | Pharmaceutical compositions containing capsaicionid | |
GB0701368D0 (en) | Novel pharmaceutical compositions | |
GB0701367D0 (en) | Novel pharmaceutical compositions | |
GB0701364D0 (en) | Novel pharmaceutical compositions | |
GB0704749D0 (en) | Novel pharmaceutical compositions | |
GB0713794D0 (en) | Novel pharmaceutical compositions | |
GB0706657D0 (en) | Pharmaceutical compositions |